IP Library › Granted Patent US 10,137,096
Granted Patent B2
US 10,137,096 · App. 15/534,137 · Granted Nov 27, 2018

Binge behavior regulators

Inventor: Ezekiel Golan (Vancouver, CA)
A61K31/135A23L2/52A61K31/255A61K31/357A61K31/36A61K31/40A61P25/30A61P25/32C12C5/02C12G3/08C12G2200/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,096
App. No.
15/534,137
Granted
Nov 27, 2018
Kind
B2
Abstract

Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.

Claims (24)

1. A method of regulating consumption of an alcoholic beverage, the method comprising administering to a subject in need thereof the compound 5-methoxy-2-aminoindan,

thereby regulating the consumption of an alcoholic beverage.

2. The method of claim 1 , wherein said consumption of an alcoholic beverage is associated with binge drinking.

3. The method of claim 1 , being for reducing an amount of alcohol consumption during a drinking session.

4. The method of claim 1 , wherein said compound or said composition is administered before, simultaneously with, or subsequent to consumption of an alcoholic beverage.

5. The method of claim 1 , wherein said compound is administered simultaneously with an alcoholic beverage.

6. The method of claim 5 , wherein said compound is incorporated in said alcoholic beverage.

7. The method according to claim 6 , wherein the amount of said compound is in the range selected from 0.15 mg/ml to 0.60 mg/ml, 0.15 mg/ml to 0.50 mg/ml, 0.15 to 0.40 mg/ml, 0.18 to 0.50 mg/ml, 0.18 to 0.40 mg/ml, 0.20 to 0.40 mg/ml, 0.20 to 0.30 mg/ml, 0.20 to 0.25 mg/ml, or 0.20 to 0.23 mg/ml.

8. The method of claim 1 , wherein said compound forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.

9. The method of claim 8 , wherein said composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate or a syrup.

10. The method of claim 8 , wherein said composition is a unit dosage form composition.

11. The method of claim 10 , wherein an amount of said compound in said unit dosage form ranges from 30 mg to 130 mg.

12. The method of claim 11 , wherein said amount of said compound is 70 mg.

13. The method of claim 1 , wherein said compound or composition is administered to a subject orally.

14. A method of regulating binge behavior, the method comprising administrating to a subject in need thereof the compound 5-methoxy-2-aminoindan,

thereby regulating the binge behavior.

15. The method of claim 14 , wherein said binge behavior is associated with alcohol consumption, eating, tobacco consumption, shopping or sexual conduct.

16. The method of claim 15 , wherein said binge behavior is binge drinking.

17. The method of claim 14 , wherein said compound forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.

18. The method of claim 17 , wherein said composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate or a syrup.

19. The method of claim 17 , wherein said composition is a unit dosage form composition.

20. The method of claim 19 , wherein an amount of said compound in said unit dosage form ranges from 30 mg to 130 mg.

21. The method of claim 20 , wherein said amount of said compound is 70 mg.

22. The method of claim 14 , wherein said compound or composition is administered to a subject orally.

Assignments (3)
CHANGE OF NAME Recorded Oct 20, 2025
From: CLEARMIND MEDICINE INC.
To: CLEARMIND LABS CORP.
Reel/Frame 072605/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2022
From: EZEKIAL GOLAN; DIET ALCOHOL CORPORATION OF THE AMERICAS
To: CYNTAR VENTURES, INC.
Reel/Frame 058796/0583 →
CHANGE OF NAME Recorded Jan 27, 2022
From: CYNTAR VENTURES, INC.
To: CLEARMIND MEDICINE INC.
Reel/Frame 058797/0479 →
Continuity (3)
Provisional Application 62089500 · Dec 9, 2014
Provisional Application 62089504 · Dec 9, 2014
Related Publication 20180085326A1 · Mar 29, 2018
Cited By (3)
US 12,350,242 US 12,357,590 US 12,454,515